LIFE-LHNG HPV DNA and RNA status, mutations of 50 genes, survival and other clinical characteristics of 270 patients with head and neck cancer described in Wichmann et al. Int. J. Canc. 2015 years packyears day ID of the patient Gender (sex) of the patient Age of the patient at the start of the study Is the patient a smoker Packyears smoked by the patient Alcohol use in g per day Primary tumor, secondary primary tumor or locoregional relapse Localization of the tumor: oral cavity (ICD-10-C02, C03, C04, C05), the oropharynx (ICD-10-C01, C09, C10), the hypopharynx (ICD-10-C12, C13), or (larynx (ICD-10-C32) Stage of cancer according to the UICC (Union for International Cancer Control) TNM classification T category describes the primary tumor site N category describes the regional lymph node involvement M category describes the presence or otherwise of distant metastatic spread Unimodal therapy was defined as either surgery only or radiotherapy only. Multimodal therapies included surgery plus post-operative radiotherapy (PORT), surgery plus post-operative radiochemotherapy (PORChT), primary concurrent radiochemotherapy (pRChT), induction-chemotherapy followed by radiotherapy (DeLOS II), induction-chemotherapy followed by surgery plus post-operative radio- or radiochemotherapy. The category palliative therapies included cases either refusing therapy or without curative option at first presentation. Consequently, they received best supportive care or palliative chemotherapy. The HPV DNA status and genotype were determined in 100 ng DNA of each sample using the line probe assay INNO-LiPA HPV Genotyping Extra (Innogenetics, Gent, Belgium). HPV16 DNA and RNA status. HPV RNA status determined by E6*I mRNA RT-PCR assay. Other HPV were coded as NA Overall survival was measured from registration date until date of death from any cause, censoring patients alive at last follow-up Was an event with respect to overall survial (death) observed or not Progression-free survival was measured from registration date until date of detection of either progression or death. Progression was defined as evidence of local recurrence, new lymph node- or distant metastasis, or second primary carcinoma. Was an event with respect to progression-free survial observed or not Consensus clusters are groups of patients determined by unsupervised clustering of patients with respect to their gene expression data Presence of at least one non-somatic mutation within the gene with at least 5% variant alleles as detetected by Ion Ampliseq Cancer Hotspot Panel v2 Presence of at least one non-somatic mutation within the gene with at least 5% variant alleles as detetected by Ion Ampliseq Cancer Hotspot Panel v2 Presence of at least one non-somatic mutation within the gene with at least 5% variant alleles as detetected by Ion Ampliseq Cancer Hotspot Panel v2 Presence of at least one non-somatic mutation within the gene with at least 5% variant alleles as detetected by Ion Ampliseq Cancer Hotspot Panel v2 Presence of at least one non-somatic mutation within the gene with at least 5% variant alleles as detetected by Ion Ampliseq Cancer Hotspot Panel v2 Presence of at least one non-somatic mutation within the gene with at least 5% variant alleles as detetected by Ion Ampliseq Cancer Hotspot Panel v2 Presence of at least one non-somatic mutation within the gene with at least 5% variant alleles as detetected by Ion Ampliseq Cancer Hotspot Panel v2 Presence of at least one non-somatic mutation within the gene with at least 5% variant alleles as detetected by Ion Ampliseq Cancer Hotspot Panel v2 Presence of at least one non-somatic mutation within the gene with at least 5% variant alleles as detetected by Ion Ampliseq Cancer Hotspot Panel v2 Presence of at least one non-somatic mutation within the gene with at least 5% variant alleles as detetected by Ion Ampliseq Cancer Hotspot Panel v2 Presence of at least one non-somatic mutation within the gene with at least 5% variant alleles as detetected by Ion Ampliseq Cancer Hotspot Panel v2 Presence of at least one non-somatic mutation within the gene with at least 5% variant alleles as detetected by Ion Ampliseq Cancer Hotspot Panel v2 Presence of at least one non-somatic mutation within the gene with at least 5% variant alleles as detetected by Ion Ampliseq Cancer Hotspot Panel v2 Presence of at least one non-somatic mutation within the gene with at least 5% variant alleles as detetected by Ion Ampliseq Cancer Hotspot Panel v2 Presence of at least one non-somatic mutation within the gene with at least 5% variant alleles as detetected by Ion Ampliseq Cancer Hotspot Panel v2 Presence of at least one non-somatic mutation within the gene with at least 5% variant alleles as detetected by Ion Ampliseq Cancer Hotspot Panel v2 Presence of at least one non-somatic mutation within the gene with at least 5% variant alleles as detetected by Ion Ampliseq Cancer Hotspot Panel v2 Presence of at least one non-somatic mutation within the gene with at least 5% variant alleles as detetected by Ion Ampliseq Cancer Hotspot Panel v2 Presence of at least one non-somatic mutation within the gene with at least 5% variant alleles as detetected by Ion Ampliseq Cancer Hotspot Panel v2 Presence of at least one non-somatic mutation within the gene with at least 5% variant alleles as detetected by Ion Ampliseq Cancer Hotspot Panel v2 Presence of at least one non-somatic mutation within the gene with at least 5% variant alleles as detetected by Ion Ampliseq Cancer Hotspot Panel v2 Presence of at least one non-somatic mutation within the gene with at least 5% variant alleles as detetected by Ion Ampliseq Cancer Hotspot Panel v2 Presence of at least one non-somatic mutation within the gene with at least 5% variant alleles as detetected by Ion Ampliseq Cancer Hotspot Panel v2 Presence of at least one non-somatic mutation within the gene with at least 5% variant alleles as detetected by Ion Ampliseq Cancer Hotspot Panel v2 Presence of at least one non-somatic mutation within the gene with at least 5% variant alleles as detetected by Ion Ampliseq Cancer Hotspot Panel v2 Presence of at least one non-somatic mutation within the gene with at least 5% variant alleles as detetected by Ion Ampliseq Cancer Hotspot Panel v2 Presence of at least one non-somatic mutation within the gene with at least 5% variant alleles as detetected by Ion Ampliseq Cancer Hotspot Panel v2 Presence of at least one non-somatic mutation within the gene with at least 5% variant alleles as detetected by Ion Ampliseq Cancer Hotspot Panel v2 Presence of at least one non-somatic mutation within the gene with at least 5% variant alleles as detetected by Ion Ampliseq Cancer Hotspot Panel v2. Mutations classified into disruptive and non-disruptive as described in Wichmann et al. Int. J. Canc. 2015 Presence of at least one non-somatic mutation within the gene with at least 5% variant alleles as detetected by Ion Ampliseq Cancer Hotspot Panel v2 Female Male Yes No No 1 to 30 g/day 31 to 60 g/day >60 g/day Primary Secondary primary Locoregional relapse Oral cavity Oropharynx Hypopharynx Larynx I II III IVA IVB IVC 1 2 3 4a 4b 0 1 2a 2b 2c 3 No Yes Unimodal Multimodal Palliative HPV16 DNA+ HPV DNA- Other HPV DNA+RNA+ DNA+RNA- DNA- TRUE FALSE TRUE FALSE 1 (Immmune Response) Atypical 2 Classical 3 Mesenchymal 4 Basal Wild type Mutant Wild type Mutant Wild type Mutant Wild type Mutant Wild type Mutant Wild type Mutant Wild type Mutant Wild type Mutant Wild type Mutant Wild type Mutant Wild type Mutant Wild type Mutant Wild type Mutant Wild type Mutant Wild type Mutant Wild type Mutant Wild type Mutant Wild type Mutant Wild type Mutant Wild type Mutant Wild type Mutant Wild type Mutant Wild type Mutant Wild type Mutant Wild type Mutant Wild type Mutant Wild type Mutant Wild type Mutant Wild type Non-disruptive Disruptive Wild type Mutant